The rate of estrogen receptor-conversion associated with tumor progression in estrogen receptor-positive breast cancer patients following adjuvant Tamoxifen administration.

Cancer Rep (Hoboken) · 2022 · PMC8789621 · PMID 34086424

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

After recurrence, only 47 patients (70.1%) were still estrogen receptor‐positive with a highly significant loss of estrogen receptor‐expression in 29.9% of cases.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.